Medicenna Announces Upcoming Oral Presentations at the 2020 Society for Neuro-Oncology Annual MeetingGlobeNewsWire • 11/18/20
Medidata Synthetic Control Arm® Supported by the US Food and Drug Administration (FDA) for Use in Medicenna Therapeutics, Corp. Phase 3 Registrational Trial in Recurrent GlioblastomaBusiness Wire • 10/28/20
Medicenna Presents Late Breaking Abstract Updating Results from Phase 2b Recurrent GBM Trial at the 36th EORTC-NCI-AACR MeetingGlobeNewsWire • 10/26/20
Medicenna Announces Upcoming Presentations at the EORTC-NCI-AACR Annual MeetingGlobeNewsWire • 10/19/20
Medicenna Provides MDNA55 rGBM Clinical Program Update Following Positive End of Phase 2 Meeting with the U.S. Food and Drug Administration (FDA)GlobeNewsWire • 10/15/20
Medicenna Reports First Quarter Fiscal 2021 Financial Results and Operational HighlightsGlobeNewsWire • 08/04/20